Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1653hxp
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Sep 29	The Philippines Inventory of Chemicals and Chemical Substances (PICCS) has been added to CHEMLIST
NEWS	3	Oct 27	New Extraction Code PAX now available in Derwent Files
NEWS	4	Oct 27	SET ABBREVIATIONS and SET PLURALS extended in Derwent World Patents Index files
NEWS	5	Oct 27	Patent Assignee Code Dictionary now available in Derwent Patent Files
NEWS	6	Oct 27	Plasdoc Key Serials Dictionary and Echoing added to Derwent Subscriber Files WPIDS and WPIX
NEWS	7	Nov 29	Derwent announces further increase in updates for DWPI

NEWS EXPRESS	FREE UPGRADE 5.0DP1 FOR STN EXPRESS 5.0 WITH DISCOVER! (WINDOWS) NOW AVAILABLE
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:37:43 ON 30 NOV 2000

=> file medline,

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'MEDLINE' ENTERED AT 16:37:58 ON 30 NOV 2000

FILE LAST UPDATED: 27 OCT 2000 (20001027/UP). FILE COVERS 1960 TO DATE.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the

MeSH 2000 vocabulary. Enter HELP THESAURUS for details.

The OLDMEDLINE file segment now contains data from 1[illegible] through 1965.
Enter HELP CONTENT for details.

Left, right, and simultaneous left and right truncation are available in the Basic Index. See HELP SFIELDS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=> s angiogenesis and (induction)

```
         8235 ANGIOGENESIS
       191343 INDUCTION
L1        669 ANGIOGENESIS AND (INDUCTION)
```

=> s muetin

```
L2          0 MUETIN
```

=> s l1 and composition

```
       107302 COMPOSITION
L3          2 L1 AND COMPOSITION
```

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 2 MEDLINE

TI Mitogen-induced expression of the fibroblast growth factor-binding protein is transcriptionally repressed through a non-canonical E-box element.

AB The fibroblast growth factor-binding protein (FGF-BP) stimulates FGF-2-mediated **angiogenesis** and is thought to play an important role in the progression of squamous cell, colon, and breast carcinomas. 12-O-Tetradecanoylphorbol-13-acetate (TPA) **induction** of the FGF-BP gene occurs through transcriptional mechanisms involving Sp1, AP-1, and CCAATT/enhancer-binding protein sites in the proximal FGF-BP gene promoter. The level of TPA **induction**, however, is limited due to the presence of a repressor element that shows similarity to a non-canonical E-box (AACGTG). Mutation or deletion of the repressor element led to enhanced **induction** by TPA or epidermal growth factor in cervical squamous cell and breast carcinoma cell lines. Repression was dependent on the adjacent AP-1 site, without discernible alteration in the binding affinity or **composition** of AP-1. We investigated the following two possible mechanisms for E-box-mediated repression: 1) CpG methylation of the core of the E-box element, and 2) binding of a distinct protein complex to this site. Point mutation of the CpG methylation site in the E-box showed loss of repressor activity. Conversely, in vitro methylation of this site significantly reduced TPA **induction**. In vitro gel shift analysis revealed distinct and TPA-dependent binding of USF1 and USF2 to the repressor element that required nucleotides within the E-box. Furthermore, chromatin immunoprecipitation assay showed that USF, c-Myc, and Max proteins were associated with the FGF-BP promoter in vivo. Overall, these findings suggested that the balance between trans-activation by AP-1 and repression through the E-box is an important control mechanism for fine-tuning the angiogenic response to growth factor-activated pathways.

ACCESSION NUMBER: 2000496098 MEDLINE
DOCUMENT NUMBER: 20435808

TITLE: [redacted]ogen-induced expression of the [redacted]broblast growth [redacted]tor-binding protein is transcr[redacted]ionally repressed through a non-canonical E-box ele[redacted]t.
AUTHOR: Harris V K; Coticchia C M; List H J; Wellstein A; Riegel A T
CORPORATE SOURCE: Department of Oncology, Vincent T. Lombardi Cancer Center, Georgetown University, Washington, D. C. 20007, USA.
CONTRACT NUMBER: CA71508 (NCI)
SOURCE: JOURNAL OF BIOLOGICAL CHEMISTRY, (2000 Sep 15) 275 (37) 28539-48.
Journal code: HIV. ISSN: 0021-9258.
PUB. COUNTRY: United States
Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals; Cancer Journals
ENTRY MONTH: 200012
ENTRY WEEK: 20001204

L3 ANSWER 2 OF 2 MEDLINE
TI Cellular and molecular mechanisms of tumor invasion.
AB This review summarizes data on cellular and molecular mechanisms underlying phenotypical characteristics of tumor cells that determine their ability for invasion. These mechanisms include dysregulation of adhesive interactions of tumor cells with each other and with extracellular matrix, protease production, locomotion reactions of tumor cells, and **induction** of **angiogenesis** in tumor. Data on structure and functions of transmembrane adhesion molecules and their ligands, molecular **composition** of adhesion structures (intercellular and focal contacts), and role of adhesion molecules as transducers of intracellular signals are considered. Alterations of expression of adhesion molecules and cytoplasmic proteins in adhesion structures and hyperphosphorylation of these molecules by oncogene products are described as a precondition of invasion activity of tumor cells. The contact interaction between circulating tumor cells and vascular endothelium is considered as the important stage of the metastatic process. Secretion of proteases by tumor cells and regulation of their activity by specific stromal inhibitors are described. Function of motogens in the acquisition by a tumor cell of locomotor phenotype facilitating invasion and impairments of topographic reactions of cells playing an important role in the invasion are considered. Attention is given to mechanisms of neoangiogenesis in the tumor providing additional ways for dissemination of tumor cells.
ACCESSION NUMBER: 1999014055 MEDLINE
DOCUMENT NUMBER: 99014055
TITLE: Cellular and molecular mechanisms of tumor invasion.
AUTHOR: Rovensky Y A
CORPORATE SOURCE: Blokhin Cancer Research Center, Russian Academy of Medical Sciences, Moscow, 115478, Russia.. jury@vasiliev.msk.su
SOURCE: BIOCHEMISTRY, (1998 Sep) 63 (9) 1029-43. Ref: 169
Journal code: CSQ. ISSN: 0006-2979.
PUB. COUNTRY: RUSSIA: Russian Federation
Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, ACADEMIC)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 199903

=> file biosis, frosti, biotechds, biotechabs, uspat, hcaplus, wpids, japio, fsta, cen, dgene, embase, scisearch

COST IN U.S. DOLLARS SINCE FILE TOTAL

FULL ESTIMATED COST [redacted] [redacted]TRY SESSION
.28 1.43

FILE 'BIOSIS' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'FROSTI' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 Leatherhead Food Research Association

FILE 'BIOTECHDS' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'USPATFULL' ENTERED AT 16:39:36 ON 30 NOV 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'HCAPLUS' ENTERED AT 16:39:36 ON 30 NOV 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'JAPIO' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 Japanese Patent Office (JPO)

FILE 'FSTA' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 International Food Information Service

FILE 'CEN' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 American Chemical Society (ACS)

FILE 'DGENE' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

FILE 'EMBASE' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:39:36 ON 30 NOV 2000
COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

=> s l1

L4 4787 L1

=> s l2

L5 2 L2

=> s l4 and l5

L6 0 L4 AND L5

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 2 USPATFULL
TI Procaryotic xylose isomerase muteins
AB Xylose isomerase (XI) muteins useful in the conversion of glucose to fructose or xylose to xylulose are obtained in usable amounts by protein

structural and recombinant DNA methods, including x-ray crystallography,
cloning, computer graphic modeling and site-directed mutagenesis and expression of the bacterial DNA sequences encoding native procaryotic xylose isomerase. These native sequences are altered to encode the xylose isomerase muteins having improved catalytic function and/or thermostability.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	91:66732 USPATFULL
TITLE:	Procaryotic xylose isomerase muteins
INVENTOR(S):	Drummond, Robert J., Richmond, CA, United States Bloch, Will, El Cerrito, CA, United States Matthews, Brian W., Eugene, OR, United States Toy, Pamela L., Oakland, CA, United States
PATENT ASSIGNEE(S):	Cetus Corporation, Emeryville, CA, United States (U.S. corporation) Univerity of Oregon, Eugene, OR, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5041378	19910820
APPLICATION INFO.:	US 1987-84479	19870811 (7)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Teskin, Robin L.	
ASSISTANT EXAMINER:	Peet, Richard C.	
LEGAL REPRESENTATIVE:	Mendel, SaraLynn	
NUMBER OF CLAIMS:	1	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 7 Drawing Page(s)	
LINE COUNT:	2240	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 2 USPATFULL
TI Enzymatically inactive, immunologically-active .beta.-galactosidase **muetin**, process for making and uses thereof
AB The present invention provides an enzymatically-inactive, immunologically-active .beta.-galactosidase mutein, wherein, in the region between the amino acids 430 and 550, at least one amino acid of the natural sequence is changed to another amino acid and the enzymatic activity does not amount to more than 1%, referred to the native enzyme.
The present invention also provides a process for the production of this
mutein. Furthermore, the present invention is concerned with the use of this mutein in the immunological determination of serum proteins by the enzyme immunoassay principle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	90:79799 USPATFULL
TITLE:	Enzymatically inactive, immunologically-active .beta.-galactosidase **muetin**, process for making and uses thereof
INVENTOR(S):	Mattes, Ralf, Stuttgart, Germany, Federal Republic of Lenz, Helmut, Tutzing, Germany, Federal Republic of Stock, Werner, Grafelfing, Germany, Federal Republic of
PATENT ASSIGNEE(S):	Boehringer Mannheim GmbH, Mannheim, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	DATE

PATENT INFORMATION: US 4963469 19901016
APPLICATION INFO.: US 1988-218816 19880712 (7

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1987-3724625	19870724

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Weimer, Elizabeth C.
ASSISTANT EXAMINER: Spiegel, Carol A.
LEGAL REPRESENTATIVE: Felfe and Lynch
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 10
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 802
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:37:43 ON 30 NOV 2000)

FILE 'MEDLINE' ENTERED AT 16:37:58 ON 30 NOV 2000
L1 669 S ANGIOGENESIS AND (INDUCTION)
L2 0 S MUETIN
L3 2 S L1 AND COMPOSITION

FILE 'BIOSIS, FROSTI, BIOTECHDS, USPATFULL, HCAPLUS, WPIDS, JAPIO, FSTA, CEN, DGENE, EMBASE, SCISEARCH' ENTERED AT 16:39:36 ON 30 NOV 2000
L4 4787 S L1
L5 2 S L2
L6 0 S L4 AND L5

=> s l4 and composition

L7 752 L4 AND COMPOSITION

=> s l7 and unit dose

L8 53 L7 AND UNIT DOSE

=> s l8 and (myocardial infarction)

L9 6 L8 AND (MYOCARDIAL INFARCTION)

=> d l9 ti abs ibib tot

L9 ANSWER 1 OF 6 USPATFULL
TI Compositions and methods for regulation of active TNF-.alpha.
AB Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active Tumor Necrosis Factor Alpha (TNF-.alpha.) can be either inhibited or augmented selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the **induction** of active cytokine secretion, such as TNF-.alpha.. The invention also relates to the initiation of a desirable immune system-related response

by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of up to about 5-8 days, preferably once a week.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:12786 USPATFULL
TITLE:	Compositions and methods for regulation of active TNF-.alpha.
INVENTOR(S):	Cohen, Irun R., Rehovot, Israel Lider, Ofer, Rehovot, Israel Cahalon, Liora, Givataim, Israel Shoseyov, Oded, Shimshon, Israel Margalit, Raanan, Rehovot, Israel
PATENT ASSIGNEE(S):	Yeda Research and Development Co. Ltd., Rehovot, Israel (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6020323	20000201
APPLICATION INFO.:	US 1995-486127	19950607 (8)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-436330, filed on 10 May 1995 which is a continuation-in-part of Ser. No. US 1993-96739, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-974750, filed on 10 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-878188, filed on 1 May 1992, now abandoned
DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Achutamurthy, Ponnathapura
ASSISTANT EXAMINER:	Ponnaluri, P.
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP
NUMBER OF CLAIMS:	17
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	65 Drawing Figure(s); 54 Drawing Page(s)
LINE COUNT:	3440

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 2 OF 6 USPATFULL

TI Methods of using low molecular weight heparins for prevention or treatment of pathological processes

AB The present invention relates to pharmaceutical compositions for the prevention and/or treatment of pathological processes involving the **induction** of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:63310 USPATFULL
TITLE:	Methods of using low molecular weight heparins for prevention or treatment of pathological processes
INVENTOR(S):	Cohen, Irun R., Rehovot, Israel Lider, Ofer, Rehovot, Israel Hershkoviz, Rami, Herzliya, Israel
PATENT ASSIGNEE(S):	Yeda Research and Development Co. Ltd., Rehovot, Israel

(non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5908837	19990601
APPLICATION INFO.:	US 1997-966315	19971107 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-457655, filed on 1 Jun 1995, now patented, Pat. No. US 5686431 which is a continuation of Ser. No. US 1995-384203, filed on 3 Feb 1995, now patented, Pat. No. US 5474987 which is a continuation of Ser. No. US 1992-878188, filed on 1 May 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1991-98028	19910502
	IL 1991-98298	19910528

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Fonda, Kathleen K.
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 6 USPATFULL
TI Methods for regulation of active TNF-.alpha.
AB Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the regulation of cytokine activity in a host. For instance, the secretion of active Tumor Necrosis Factor Alpha (TNF-.alpha.) can be either inhibited or augmented selectively by administration to the host of an effective amount of a substance of the invention. Thus, the present invention also relates to pharmaceutical compositions and their use for the prevention and/or treatment of pathological processes involving the **induction** of active cytokine secretion, such as TNF-.alpha.. The invention also relates to the initiation of a desirable immune system-related response by the host to the presence of activators, including pathogens. The substances and pharmaceutical compositions of the present invention may be administered daily, at very low effective doses, typically below 0.1 mg/kg human, or at intervals of tip to about 5-8 days, preferably once a week.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:7369 USPATFULL
TITLE: Methods for regulation of active TNF-.alpha.
INVENTOR(S): Cohen, Irun R., Rehovot, Israel
Lider, Ofer, Rehovot, Israel
Cahalon, Liora, Givataim, Israel
Shoseyov, Oded, Shimshon, Israel
Margalit, Raanan, Rehovot, Israel
PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Israel (non-U.S. corporation)

	NUMBER	DATE

	NUMBER	DATE	
PATENT INFORMATION:	US 5861382	19990119	
	WO 9411006	19940526	
APPLICATION INFO.:	US 1995-436330	19950629	(8)
	WO 1993-US10868	19931109	
		19950629	PCT 371 date
		19950629	PCT 102(e) date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-96739, filed on 23 Jul 1993, now abandoned And a continuation-in-part of Ser. No. US 1992-974750, filed on 10 Nov 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-878188, filed on 1 May 1992, now abandoned And a continuation of Ser. No. US 1995-384203, filed on 3 Feb 1995, now patented, Pat. No. US 5474987

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Achutamurthy, Ponnathapura
ASSISTANT EXAMINER: Ponnaluri, Padmashri
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 65 Drawing Figure(s); 54 Drawing Page(s)
LINE COUNT: 3391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 6 USPATFULL

TI Integrin receptor antagonists

AB This invention relates to novel heterocycle compounds including but not limited to 3-[3-[3-(imidazolin-2-yl amino)propyloxy]isoxazol-5-ylcarbonylamino]-2-(benzyloxycarbonylamino)-propionic acid, which are useful as antagonists of the .alpha..sub.v .beta..sub.3 and related integrin receptors, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of cell adhesion and the treatment of angiogenic disorders, inflammation, bone degradation, tumors, metastases, thrombosis, and other cell aggregation-related conditions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:7077 USPATFULL
TITLE: Integrin receptor antagonists
INVENTOR(S): Voss, Matthew Ernst, Lincoln University, PA, United States
Jadhav, Prabhakar Kondaji, Wilmington, DE, United States
Smallheer, Joanne Marie, Landenberg, PA, United States
Batt, Douglas Guy, Wilmington, DE, United States
Pitts, William John, Conshohocken, PA, United States
Wityak, John, West Grove, PA, United States
PATENT ASSIGNEE(S): The DuPont Merck Pharmaceutical Company, Wilmington, DE, United States (U.S. corporation)

	NUMBER	DATE	
PATENT INFORMATION:	US 5710159	19980120	
APPLICATION INFO.:	US 1996-647132	19960509	(8)

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: McKane, Joseph
LEGAL REPRESENTATIVE: Ferguson, Blair Q.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
LINE COUNT: 6665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 6 USPATFULL
TI Methods of using low molecular weight heparins for treatment of pathological processes
AB The present invention relates to methods for the prevention and/or treatment of pathological processes involving the **induction** of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular Weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	97:104459 USPATFULL
TITLE:	Methods of using low molecular weight heparins for treatment of pathological processes
INVENTOR(S):	Cohen, Irun R., Rehovot, Israel Lider, Ofer, Rehovot, Israel Hershkoviz, Rami, Herzliya, Israel
PATENT ASSIGNEE(S):	Yeda Research and Development Co., Ltd., Israel (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5686431	19971111
APPLICATION INFO.:	US 1995-457655	19950601 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1995-384203, filed on 3 Feb 1995, now patented, Pat. No. US 5474987 which is a continuation of Ser. No. US 1992-878188, filed on 1 May 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1991-98028	19910502
	IL 1991-98298	19910528

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Fonda, Kathleen K.
LEGAL REPRESENTATIVE:	Pennie & Edmonds
NUMBER OF CLAIMS:	4
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT:	907

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 6 USPATFULL
TI Methods of using low molecular weight heparins treatment of pathological processes
AB The present invention relates to methods for the prevention and/or treatment of pathological processes involving the **induction** of TNF-.alpha. secretion comprising a pharmaceutically acceptable carrier and a low molecular weight heparin (LMWH). In the pharmaceutical compositions of the present invention, the LMWH is present in a low effective dose and is administered at intervals of about 5-8 days. Furthermore, the LMWH is capable of inhibiting in vitro TNF-.alpha. secretion by resting T cells and/or macrophages in response to T cell-specific antigens, mitogens, macrophage activators, disrupted extracellular matrix (dECM), laminin, fibronectin, and the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	95:110435 USPATFULL
TITLE:	Methods of using low molecular weight heparins treatment of pathological processes
INVENTOR(S):	Cohen, Irun R., Herzliya, Israel Lider, Ofer, Herzliya, Israel Hershkoviz, Rami, Herzliya, Israel
PATENT ASSIGNEE(S):	Yeda Research and Development Co. Ltd., Israel (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5474987	19951212
APPLICATION INFO.:	US 1995-384203	19950203 (8)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1992-878188, filed on 1 May 1992, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	IL 1991-98028	19910502
	IL 1991-98298	19910528

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Robinson, Douglas W.
ASSISTANT EXAMINER:	Fonda, Kathleen Kahler
LEGAL REPRESENTATIVE:	Pennie & Edmonds
NUMBER OF CLAIMS:	6
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT:	860

CAS INDEXING IS AVAILABLE FOR THIS PATENT.